New drug targets Alzheimer's proteins in spinal fluid
NCT ID NCT07598370
First seen May 21, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This early-stage study is testing an experimental drug called LY3439539 in 30 people with mild-to-moderate Alzheimer's disease. The main goal is to see if the drug changes certain proteins in the spinal fluid that are linked to Alzheimer's. Participants will receive the drug through an IV and have monthly visits for about 9 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health - Heidelberg Repatriation Hospital
RECRUITINGIvanhoe, 3079, Australia
Contact Phone: •••-•••-••••
Contact
-
Flinders Medical Centre
NOT_YET_RECRUITINGAdelaide, 5042, Australia
Contact Phone: •••-•••-••••
Contact
-
Lilly Centre for Clinical Pharmacology
RECRUITINGSingapore, 138623, Singapore
Contact Phone: •••-•••-••••
Contact
-
Macquarie University Hospital
RECRUITINGMacquarie University, 2109, Australia
Contact Phone: •••-•••-••••
Contact
-
Southern Neurology
RECRUITINGKogarah, 2217, Australia
Contact Phone: •••-•••-••••
Contact
-
The Alfred
RECRUITINGMelbourne, 3004, Australia
Contact Phone: •••-•••-••••
Contact
-
University of the Sunshine Coast Clinical Trial Centre
NOT_YET_RECRUITINGBirtinya, 4575, Australia
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3439539
What this could lead to
If successful, this could help researchers understand how LY3439539 affects Alzheimer's-related brain changes, potentially guiding future treatments.
What could go wrong
This is a very early, small Phase 1 study focused on biomarkers, not symptoms. It may not show any benefit, and the drug could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.